Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference
Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo
- Product Code
- ILEA001514803
- Registered date
- 2023/7/07 00:00:00
- Credit
- THE NIKKAN KOGYO SHIMBUN / Kyodo News Images
- Media source
- THE NIKKAN KOGYO SHIMBUN
- Media size
- 3000 × 2000 pixel
- Deployment size
- 1.02(MB)*
- Special instruction
-
**The text may be generated by an automatic translation system**
*File size when opened in Photoshop, etc.